These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 19955913)

  • 1. Optimal management of recurrent ovarian cancer.
    Markman M
    Int J Gynecol Cancer; 2009 Dec; 19 Suppl 2():S40-3. PubMed ID: 19955913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference.
    Stuart GC; Kitchener H; Bacon M; duBois A; Friedlander M; Ledermann J; Marth C; Thigpen T; Trimble E; ;
    Int J Gynecol Cancer; 2011 May; 21(4):750-5. PubMed ID: 21543936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds.
    Monk BJ; Coleman RL
    Int J Gynecol Cancer; 2009 Dec; 19 Suppl 2():S63-7. PubMed ID: 19955917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal treatment for relapsing ovarian cancer.
    Ledermann JA; Kristeleit RS
    Ann Oncol; 2010 Oct; 21 Suppl 7():vii218-22. PubMed ID: 20943618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical trials and decision-making strategies for optimal treatment of relapsed ovarian cancer.
    Ledermann JA; Raja FA
    Eur J Cancer; 2011 Sep; 47 Suppl 3():S104-15. PubMed ID: 21943964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The global impact of the Gynecologic Cancer InterGroup in enhancing clinical trials in ovarian cancer.
    Bacon M; Kitchener H; Stuart GC; Vermorken JB;
    Int J Gynecol Cancer; 2011 May; 21(4):746-9. PubMed ID: 21543935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recommendations of the Fertility Task Force of the European Society of Gynecologic Oncology about the conservative management of ovarian malignant tumors.
    Morice P; Denschlag D; Rodolakis A; Reed N; Schneider A; Kesic V; Colombo N;
    Int J Gynecol Cancer; 2011 Jul; 21(5):951-63. PubMed ID: 21697684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical trials in recurrent ovarian cancer.
    Friedlander M; Trimble E; Tinker A; Alberts D; Avall-Lundqvist E; Brady M; Harter P; Pignata S; Pujade-Lauraine E; Sehouli J; Vergote I; Beale P; Bekkers R; Calvert P; Copeland L; Glasspool R; Gonzalez-Martin A; Katsaros D; Kim JW; Miller B; Provencher D; Rubinstein L; Atri M; Zeimet A; Bacon M; Kitchener H; Stuart GC;
    Int J Gynecol Cancer; 2011 May; 21(4):771-5. PubMed ID: 21543939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian cancer and the battle of the specialists.
    McGuire WP
    J Clin Oncol; 2007 Aug; 25(23):3554-5; author reply 3557-8. PubMed ID: 17687166
    [No Abstract]   [Full Text] [Related]  

  • 10. Joint ENGOT and GOG Foundation requirements for trials with industry partners.
    Vergote I; Coleman RL; Pignata S; Bookman MA; Marth C; Herzog TJ; Gonzalez Martin A; Copeland LJ;
    Int J Gynecol Cancer; 2019 Sep; 29(7):1094-1097. PubMed ID: 31320391
    [No Abstract]   [Full Text] [Related]  

  • 11. Modern management of recurrent ovarian carcinoma. A systematic approach to a chronic disease.
    Michener CM; Belinson JL
    Oncology (Williston Park); 2005 Sep; 19(10):1277-85; discussion 1285, 1288, 1293. PubMed ID: 16285224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and hematologic toxicity of salvage chemotherapy following stem cell-supported high-dose chemotherapy in women with recurrent ovarian cancer.
    Cook S; Penson R; Duska L; Nikrui N; Goodman A; Fuller A; Seiden M
    Gynecol Oncol; 2000 Apr; 77(1):48-54. PubMed ID: 10739690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing health-related quality of life in gynecologic oncology.
    Nordin AJ; Greimel E;
    Int J Gynecol Cancer; 2010 Nov; 20(8):1301. PubMed ID: 21051967
    [No Abstract]   [Full Text] [Related]  

  • 14. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Better prognosis in epithelial ovarian cancer].
    Högberg T; Anderson H
    Lakartidningen; 1997 Jan; 94(1-2):28-31. PubMed ID: 9053599
    [No Abstract]   [Full Text] [Related]  

  • 16. Management of recurrent epithelial ovarian carcinoma.
    Vasey PA
    Aust N Z J Obstet Gynaecol; 2005 Aug; 45(4):269-77. PubMed ID: 16029291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing management of recurrent epithelial ovarian cancer: a critical need for evidence-based data.
    Markman M
    Oncology; 2006; 71(5-6):309-11. PubMed ID: 17873498
    [No Abstract]   [Full Text] [Related]  

  • 18. Influence of the gynecologic oncologist on the survival of ovarian cancer patients.
    Chan JK; Kapp DS; Shin JY; Husain A; Teng NN; Berek JS; Osann K; Leiserowitz GS; Cress RD; O'Malley C
    Obstet Gynecol; 2007 Jun; 109(6):1342-50. PubMed ID: 17540806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic therapy for ovarian cancer: current status and new treatments.
    Ozols RF
    Semin Oncol; 2006 Apr; 33(2 Suppl 6):S3-11. PubMed ID: 16716797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors in stage I ovarian carcinoma.
    Vergote I
    Verh K Acad Geneeskd Belg; 2001; 63(3):257-71; discussion 272-6. PubMed ID: 11499346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.